

Cutaneous Lupus Erythematosus – Pipeline Insight, 2020

<https://marketpublishers.com/r/C96FA0F8F7EEN.html>

Date: September 2020

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C96FA0F8F7EEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Cutaneous Lupus Erythematosus – Pipeline Insight, 2020," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cutaneous Lupus Erythematosus Understanding

Cutaneous Lupus Erythematosus: Overview

Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:

LE-specific cutaneous LE has been classified as acute, subacute, intermittent

and chronic. Lesions may be localised or generalised. In LE-specific cutaneous LE, lesions are often induced by exposure to sunlight.

LE-nonspecific cutaneous LE may relate to systemic LE or another autoimmune disease.

Diagnosis

A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test).

Treatment

Treatment may vary depending upon type of Cutaneous Lupus Erythematosus: The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.

Local therapy

Potent or ultrapotent topical steroids are applied to chronic discoid LE plaques.

Calcineurin inhibitors, pimecrolimus cream or tacrolimus ointment can be used instead of topical steroids.

Intralesional corticosteroid can be injected into small lesions resistant to topical therapy.

Topical retinoids, calcipotriol and imiquimod have also been reported to be helpful in a few patients.

Cosmetic camouflage may be used to disguise unsightly plaques.

Systemic therapy

Treatment for cutaneous and systemic LE may include:

Antimalarials especially hydroxychloroquine

Immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin

Retinoids, ie acitretin, isotretinoin

Systemic corticosteroids

If sun protection is strict, vitamin D supplementation.

Cutaneous Lupus Erythematosus Emerging Drugs Chapters

This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous Lupus Erythematosus Emerging Drugs

Filgotinib: Galapagos/Gilead Sciences

Filgotinib (GLPG0634/GS-6034) is a potent and selective inhibitor of JAK1,7 which is currently under investigation for the treatment Cutaneous Lupus Erythematosus. It is currently in phase II stage of development.

VIB7734: Viela Bio.

VIB7734 potentially represents a novel treatment for autoimmune diseases caused by the overproduction of type I interferons and other cytokines secreted by a type of dendritic cell called pDCs. VIB7734 is designed to target and bind to ILT7, a cell surface molecule specific to pDCs, leading to their depletion. The benefits are multifold as this depletion may also decrease other inflammatory cytokines such as TNF-a and IL-6, which are critical to the pathogenesis of a number of autoimmune diseases. Viela Bio have completed a phase Ia single-ascending dose trial in patients with various

autoimmune diseases including cutaneous lupus erythematosus (CLE).

HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics

Hoth has entered a partnership agreement with Zyl? Therapeutics Inc to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE). HT-005 Z-Pods includes a novel topical delivery matrix (Z-Pods) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients. The HT-005 Z-Pods™ product is currently in the early preclinical stage of development.

Further product details are provided in the report

Cutaneous Lupus Erythematosus: Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cutaneous Lupus Erythematosus

There are approx. 15+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus. The companies which have their Cutaneous Lupus Erythematosus drug candidates in the most advanced stage, i.e. phase II include Galapagos/Gilead Sciences and others

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravenous

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous Lupus Erythematosus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous Lupus Erythematosus.

In May 2020, Viela Bio announced positive interim phase Ib data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with cutaneous lupus erythematosus (CLE).

In July 2019, Gilead Sciences and Galapagos stated that they have entered into

a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

In May 2020, Hoth Therapeutics announced it has completed a strategic investment in Zyl? Therapeutics.

Cutaneous Lupus Erythematosus Report Insights

Cutaneous Lupus Erythematosus Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cutaneous Lupus Erythematosus Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cutaneous Lupus Erythematosus drugs?

How many Cutaneous Lupus Erythematosus drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous Lupus Erythematosus?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous Lupus Erythematosus therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cutaneous Lupus Erythematosus and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Hoth Therapeutics

Zylo Therapeutics

Galapagos

Gilead Sciences

Viela Bio

Biogen Idec

Rigel Pharmaceuticals

Amgen/AstraZeneca

Key Products

GSK2646264

Filgotinib

Daxdilimab

BIIB 059

R 333

AEA-loaded Z-pods

Prezalumab

Contents

Introduction

Executive Summary

Cutaneous Lupus Erythematosus: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cutaneous Lupus Erythematosus – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Cutaneous Lupus Erythematosus companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Cutaneous Lupus Erythematosus Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Filgotinib: Galapagos/Gilead Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

VIB7734: Viela Bio.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics

Product Description

Research and Development

Product Development Activities

Inactive Products

Comparative Analysis

Cutaneous Lupus Erythematosus Key Companies**Cutaneous Lupus Erythematosus Key Products****Cutaneous Lupus Erythematosus- Unmet Needs****Cutaneous Lupus Erythematosus- Market Drivers and Barriers****Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion****Cutaneous Lupus Erythematosus Analyst Views****Cutaneous Lupus Erythematosus Key Companies****Appendix**

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cutaneous Lupus Erythematosus

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cutaneous Lupus Erythematosus

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Cutaneous Lupus Erythematosus – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/C96FA0F8F7EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C96FA0F8F7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970